MIR-147B REGULATED PROLIFERATION
AND APOPTOSIS OF GASTRIC CANCER CELLS
BY TARGETING CPEB2 VIA THE PTEN PATHWAY
Tao K.1,2, Dong J-H.2, Wang D.1, Li F.2†#, Zhang Z-T.#1*
*Corresponding Author: Zhong-Tao Zhang, MD, Email: sxzhangzhongtao@sina.com, ORCID ID: 0000-0002-1184-2591
#: Zhong-Tao Zhang and Feng Li contributed equally to the article
†: Co-corresponding author: Feng Li, Email: sxlifengwobuxin@sina.com, ORCID: 0000-0002-7322-422X
page: 10
download article in pdf format
|
|
Abstract
The present study has been performed to illustrate the
role and mechanism of microRNA-147b (miR-147b) in
the cellular viability and apoptosis of gastric cancer (GC)
cells. The GC tissues of 50 patients with complete data
and the adjacent tissues were selected from Shanxi Cancer
Hospital, and 3 pairs of tissues were randomly selected
for microarray detection of high-expressing microRNAs.
The expressions of miR-147b were quantified in numerous
GC cell lines, i.e., BGC-823, SGC-7901, AGS, MGC-803
and MKN-45, normal tissue cell lines and 50 pairs of
gastric cancer tissues. Moreover, two cell lines of miR-
147b high-expressing used PCR quantitative analysis were
selected for transfection experiments. The differentially
expressed miR-147b was screened from 3 pairs of samples
by miRNA chip. The expression ofmiR-147b was found
highly expressed in gastric cancer tissues of 50 pairs of
gastric cancer and adjacent tissues. The miR-147b found
in diverse range in each of GC cell line. Therefore, two
cell lines, BGC-823 and MGC-803, with relatively high
expression levels of miR-147b were selected for further
analysis and research. Scratch analysis results showed
that compared with miR-147b NC, the miR-147b inhibitor
group inhibited GC cell growth and reduced cell migration.
The early apoptosis of MGC-803, and BGC-823 cells
was enhanced by miR-147b inhibitor. miR-147b inhibitor
significantly repressed the proliferation of BGC-823 and
MGC-803 cells. Our study showed that the high expression
of miR-147b is positively correlated with the occurrence
and development of gastric cancer.
|
|
|
|
 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
|
